⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfurous Acid SCHEMBL28930563 | 0.76 | CA1 (0.60) | — | |
| Sulfurous Acid SCHEMBL8740827 | 0.76 | — | — | |
| Sulfurous Acid SCHEMBL11788077 | 0.70 | — | — | |
| SCHEMBL5225222 | 0.67 | — | — | |
| SCHEMBL27538455 | 0.67 | — | — | |
| Sulfurous Acid SCHEMBL5680970 | 0.64 | — | — | |
| Sulfurous Acid SCHEMBL2877263 | 0.64 | — | — | |
| SCHEMBL17771931 | 0.64 | — | — | |
| SCHEMBL42308 | 0.64 | — | — | |
| Dimethylamine SCHEMBL8024155 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4180431-A1 | CHEMICAL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2023-05-17 | — | — | EP | disclosed |
| WO-2022159818-A1 | POLY(ADP-RIBOSE) GLYCOHYDROLASE (PARG) INHIBITORS AGAINST COVID MACRODOMAIN AND METHODS OF USING THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-28 | — | — | WO | disclosed |
| US-20160311807-A1 | METHODS TO TREAT LYMPHOPLASMACYTIC LYMPHOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150246913-A1 | BONE MARROW ON X CHROMOSOME KINASE (BMX) INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-09-03 | — | — | US | disclosed |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-18 | — | — | US | disclosed |
| US-8435411-B2 | Methods and compositions for the removal of impurities from an impurity-loaded organic salt | CYTEC TECHNOLOGY CORP. (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2212281-B1 | ARYLSULFONAMIDES WITH ANALGESIC ACTIVITY | BOEHRINGER INGELHEIM INT (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100120157-A1 | Methods of Using Sulfur Nucleophiles as Improved Alternatives to Sodium Bisulfite for Methylated DNA Analysis | Life Technologies Corporation (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2009094443-A1 | DIFLUORINATED TRIPEPTIDES AS HCV SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-30 | — | — | WO | disclosed |
| US-20090099161-A1 | Substituted Imidazoquinolines and Imidazonaphthyridines | COLEY PHARMACEUTIAL GROUP, INC. (NY) | 2009-04-16 | — | — | US | disclosed |
| US-20090042925-A1 | OXIME SUBSTITUTED IMIDAZOQUINOLINES | COLEY PHARMACEUTICAL GROUP, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20080318998-A1 | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| WO-2008021733-A2 | TETRAZOLYL ACYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20060063189-A1 | Methods of using sulfur nucleophiles as improved alternatives to sodium bisulfite for methylated DNA analysis | APPLERA CORPORATION APPLIED BIOSYSTEMS GROUP (US) | 2006-03-23 | — | — | US | disclosed |